- have liver problems
- plan to have surgery
- have chicken pox or measles or have recently been near anyone with chicken pox or measles
- have an infection
- have high blood sugar levels (prediabetes or diabetes)
- have glaucoma or cataracts
- have a family history of diabetes or glaucoma
- have or have had tuberculosis
- have high blood pressure (hypertension)
HOW SHOULD I TAKE TARPEYO?
It is important to take TARPEYO exactly as your healthcare provider tells you. Your healthcare provider will decide how long you should take TARPEYO. Do not stop taking TARPEYO without first talking with your healthcare provider.

4 capsules of TARPEYO should be taken once a day and swallowed whole

Take TARPEYO in the morning, at least 1 hour before your morning meal

Don’t crush, chew, or open TARPEYO. Don’t eat grapefruit, or drink grapefruit juice, while on TARPEYO treatment
ONCE-DAILY DOSING
The recommended course of therapy based on the clinical study is 9 months at 16 mg (4 capsules per day). When your doctor decides that you no longer need to take TARPEYO, you should take 8 mg (2 capsules) per day for 2 weeks.
WHEN DID PATIENTS START TO SEE RESULTS IN THE STUDY?
The TARPEYO study results are based on 9 months of treatment
- Protein levels began to decrease after 3 months
- Protein levels decreased by 34% at month 9
- Protein levels continued to decrease to 53% for 3 months after treatment (months 9-12)


Data presented prior to or beyond the first 9 months should be interpreted with caution.
*Patients did not receive treatment during the 3-month follow-up phase.
FREQUENTLY ASKED QUESTIONS
WHAT IS TARPEYO?
TARPEYO is a prescription medicine used to reduce levels of protein in the urine (proteinuria) in adults with IgA Nephropathy (IgAN) who are at high risk of disease progression. TARPEYO was specifically designed for IgAN.
WHEN WAS TARPEYO APPROVED?
TARPEYO was FDA-approved in December 2021, and is available by prescription. This approval is based on reduction in proteinuria. Confirmatory clinical trial results are needed to verify the clinical benefit of slowing kidney function decline.
HOW IS TARPEYO THOUGHT TO WORK?
TARPEYO is designed to deliver treatment to an area of the gut thought to play a role in IgAN. Types of cells in the gut are thought to be responsible for the production of IgA1. These types of IgA1 can build up in the kidneys and cause IgAN. TARPEYO can reduce the amount of this antibody.†
HOW IS TARPEYO DIFFERENT FROM OTHER STEROIDS IʼVE BEEN PRESCRIBED FOR IgAN?
TARPEYO is the first FDA-approved treatment to reduce protein levels in the urine of patients with IgAN and was designed for delivery to the area where the disease is thought to come from. Other steroids have not established efficacy or safety and are not FDA approved for IgAN.
WHAT DID TARPEYO CLINICAL STUDIES SHOW?
In a clinical study at 9 months, there was a significant 34% reduction in the level of protein in urine seen in the TARPEYO-treated group compared with a 5% reduction in the placebo plus blood pressure medication group.†
The most common side effects (occurring in ≥10% of patients treated with TARPEYO at a higher incidence than blood pressure medication alone) were: high blood pressure; swelling of the lower legs, ankles, and feet; muscle cramp; and acne.
HOW OFTEN WILL I NEED TO MONITOR MY LAB VALUES WHILE TAKING TARPEYO?
You will need to have your labs measured to determine how well you are responding to treatment. Your doctor will decide which lab values and how often they will monitor them. With TARPEYO, there is no FDA-required monthly lab monitoring, as seen with other products.
IS THERE A PROGRAM THAT CAN HELP PROVIDE FINANCIAL ASSISTANCE FOR TARPEYO?
Yes, TARPEYO TouchpointsTM is a program that was developed to help support your treatment journey. A Care Navigator can help with financial support options you may be eligible for. They can also connect you with nurses and resources, and help track your prescription shipment each month.
*It has not been established to what extent the efficacy of TARPEYO is from local effects (in the gut) vs systemic effects (in circulation).
†In Part A of the TARPEYO clinical study, 97 patients received TARPEYO plus blood pressure medication, and 102 patients received placebo plus blood pressure medication.
ASK YOUR HEALTHCARE PROVIDER ABOUT TARPEYO
Here are some questions you may want to ask your doctor to determine if TARPEYO is right for you.

ADVOCATE FOR YOURSELF
- Can we discuss a disease-specific treatment option like TARPEYO?
- Based on my recent lab results, could TARPEYO be an option for me?
- What makes TARPEYO different from other treatments that you may prescribe to treat IgAN?

DISCUSS BENEFITS AND RISKS
- What are the potential benefits and risks of taking TARPEYO to treat my IgAN?
- What results might I expect once Iʼm on TARPEYO?

STARTING TARPEYO
- How do I take TARPEYO?
- Do I take TARPEYO along with another medication?
- How long will I need to take TARPEYO?

TRACKING RESULTS
- When can I expect to see results?
- How often should I schedule my follow-up appointments?
- What should I do if I experience any side effects while taking TARPEYO?